Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946516 · ClinicalTrials.gov registry record
S1204, Viral Screening in Newly Diagnosed Cancer Patients
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 3,051
- Enrollment target
NCT01946516: Completed study, sponsored by SWOG Cancer Research Network.
NCT01946516 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 3,051 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01946516 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 3,051 participants
- Enrollment target
Study Summary
The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.
Primary Outcome
An estimate of the prevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection among newly diagnosed cancer participants presenting to SWOG-affiliated community and academic oncology clinics.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,051 participants |
| Start Date | 2013-08-29 |
| Est. Completion | 2022-10-13 |
What the finished NCT01946516 record still lists
NCT01946516 is an observational study that tracks outcomes without assigning an intervention. Its 3,051 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01946516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01946516 about?
NCT01946516 is a clinical study titled "S1204, Viral Screening in Newly Diagnosed Cancer Patients". The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.
What is the current status of trial NCT01946516?
This trial is currently completed. The enrollment target is 3,051 participants. The study started on 2013-08-29. Estimated completion is 2022-10-13.
Who is sponsoring clinical trial NCT01946516?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI